5:45 PM
 | 
Jul 09, 2007
 |  BC Extra  |  Company News

Claims of Ariad's NF-kappa B patent rejected

The U.S. Patent and Trademark Office rejected certain claims of ARIA's patent covering methods of treating human disease by regulating NF-kappa B signaling activity based on prior art. The rejected claims include those being asserted in a patent infringement suit against Eli Lilly (LLY), as...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >